Skip to main content
. Author manuscript; available in PMC: 2011 Oct 29.
Published in final edited form as: Cell. 2010 Oct 29;143(3):355–366. doi: 10.1016/j.cell.2010.09.043

Figure 3. IL-6 and Timp-1 are chemoprotective in vitro and in vivo.

Figure 3

(A) A graph showing the fold change in lymphoma cell number 72 hours after treatment with doxorubicin as a single agent or doxorubicin plus recombinant IL-6. The data are represented as mean +/- SEM (n=4 independent experiments). (B) A graph showing the relative survival of cultured lymphoma cells at 24 hour intervals following treatment with doxorubicin alone, doxorubicin plus recombinant IL-6 or Timp-1, or doxorubicin plus both IL-6 and Timp-1. The data are represented as mean +/- SEM (n=3 independent experiments). (C) A schematic diagram of the lymphoma transplant experiment, showing injection of IL-6+/+ lymphoma cells into both IL-6+/+ and IL-6-/- recipients. (D) A Kaplan-Meier curve showing post-treatment survival of IL-6+/+ (n=17) or IL-6-/- (n=5) mice bearing IL-6+/+ lymphomas. All mice were treated with a single dose of 10mg/kg doxorubicin. The p value was calculated using a logrank test. (E) H&E stained sections of lymphomas 72 hours following doxorubicin treatment. The black dotted line shown in the thymus from the IL-6+/+ recipient mouse demarcates a zone of surviving lymphoma cells that is absent in the other sections. Representative fields are shown at 20× magnification. See also Figure S2.